Day: July 26, 2011

Baxter Presents Preclinical Data on its Investigational Compound BAX 499 for Potential Subcutaneous Hemophilia Therapy and Final Phase I Data on Recombinant von Willebrand Factor

FOR IMMEDIATE RELEASEMedia ContactsDoreen Eaton, (805) 372-3417 Marie Kennedy, (805) 372-3543Investor ContactsMary Kay Ladone, (847) 948-3371 Clare Trachtman, (847) 948-3085BAXTER PRESENTS PRECLINICAL DATA AT ISTH ON ITS INVESTIGATIONAL COMPOUND BAX 499 FOR POTENTIAL SUBCUTANEOUS HEMOPHILIA THERAPY AND FINAL PHASE I DATA ON RECOMBINANT VON WILLEBRAND FACTORThree Baxter Scientists Granted Prestigious ISTH Young Investigators AwardKYOTO, Japan, […]